Insider selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP sells $35,395.00 in stock. September 14, 2026 Key points. * ANI Pharmaceuticals VP Meredith Cook sold 500 shares at an average price of $70.79, totaling $35,395, under a pre-arranged Rule 10b5-1 trading plan. She continues to own 73,924 shares, and has made two similar 500-share sales since July. * ANIP recently traded near its 12-month low at $70.40, while the company reported quarterly EPS of $2.21 and revenue of $266.04 million, beating analyst estimates and marking 25.8% year-over-year revenue growth. * Analyst sentiment remains positive overall, with a "Moderate Buy" consensus and an average price target of $105.57; institutional investors own approximately 76.05% of the company's stock. * Five stocks we like better than ANI Pharmaceuticals. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $70.79, for a total value of $35,395.00. Following the sale, the vice president directly owned 73,924 shares of the company's stock, valued at $5,233,079.96. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Meredith Cook also recently made the following trade(s): * On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. * On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $81.84, for a total value of $40,920.00. ANI Pharmaceuticals price performance. ANIP stock traded up $0.21 on Monday, reaching $70.40. 357,649 shares of the company's stock were exchanged, compared to its average volume of 331,768. The stock has a fifty day moving average of $76.97 and a 200-day moving average of $78.17. ANI Pharmaceuticals, Inc. has a twelve month low of $69.58 and a twelve month high of $99.39. The firm has a market cap of $1.62 billion, a PE ratio of 15.17 and a beta of 0.45. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter last year, the company earned $1.80 earnings per share. ANI Pharmaceuticals's quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year. Institutional trading of ANI Pharmaceuticals. A number of hedge funds have recently made changes to their positions in ANIP. California State Teachers Retirement System grew its holdings in ANI Pharmaceuticals by 7,977.4% during the 2nd quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company's stock valued at $164,200,000 after purchasing an additional 1,959,017 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of ANI Pharmaceuticals by 19.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company's stock worth $43,399,000 after acquiring an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock valued at $40,843,000 after purchasing an additional 43,523 shares during the last quarter. Ranger Investment Management L.P. acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at approximately $28,406,000. Finally, Deutsche Bank AG purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $26,775,000. Hedge funds and other institutional investors own 76.05% of the company's stock. Analyst Ratings changes. Several equities research analysts recently commented on ANIP shares. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price objective on the stock. Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Guggenheim dropped their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research report on Monday, August 10th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $105.57. Discover more 5G Stocks Guide Stock Ratings Screener Dividend Screener Service About ANI Pharmaceuticals. ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas. ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider ANI Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list. While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public. Continue following MarketBeat

ANI Pharmaceuticals trades at $76.15 per share, showing a 3% return over six months, underperforming the S&P 500's 11.7% gain. The company develops, manufactures, and markets branded and generic prescription pharmaceuticals with a portfolio of 116 products. The pharmaceutical firm demonstrated strong momentum with revenue growing at 35.6% compound annual growth rate over five years. Its free cash flow margin expanded by 38.5 percentage points during the same period, reaching 17.7% over the trailing 12 months. However, ANI Pharmaceuticals faces scale challenges with just $978.4 million in revenue over the past year. This smaller size limits its ability to build customer trust in the heavily regulated healthcare sector, though it allows for faster potential growth with proper execution.